Likelihood of Approval and Phase Transition Success Rate Model – Reparixin in Coronavirus Disease 2019 (COVID-19) Pneumonia
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Reparixin in Coronavirus Disease 2019 (COVID-19) Pneumonia report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Reparixin in Coronavirus Disease 2019 (COVID-19) Pneumonia Drug Details:
Reparixin (Repertaxin) is under development to improve the efficacy of transplantation after pancreatic islet B-cell (rare) (allogenic and autologous setting) transplant, HER2 negative metastatic breast cancer, acute respiratory distress syndrome, pneumonia associated COVID -19. The drug candidate is administered through oral route in the form of tablet and through intravenous infusion. It acts by targeting CXC chemokine receptors CXCR1 and CXCR2.It was also under development for the treatment of community-acquired pneumonia (CAP), delayed graft dysfunction after kidney transplantation, cancer related fatigue in patients with locally advanced or metastatic breast cancer, metastatic triple-negative breast cancer, delayed graft function and primary graft dysfunction after lung transplantation and liver transplantation.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Reparixin LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports